Incyte Corp. (INCY)

Company Description

Incyte Corporation (Wilmington, Delaware) is a biopharmaceutical company that is focused on developing novel small molecule therapies for the treatments of cancers and inflammatory diseases. The company obtained approval in the U.S. for Jakafi in late 2011, which is a first-in class compound for myeloproliferative disorders that inhibits the intraceullar Janus kinases (Jak) signaling pathway; the ex-U.S. ruxolitinib rights have been licensed to Novartis in a deal potentially valued at up to $1 billion. INCY’s second key pipeline product is INCB28050, which is a second-generation oral Jak inhibitor in development for autoimmune disorders such as rheumatoid arthritis. The company has licensed global rights to INCB28050 to Lilly, and plans to co-develop the agent in rheumatoid arthritis. Behind ruxolitinib and INCB28050, INCY has several earlierstage Phase I/II oncology assets, which have different mechanisms of action, and a fully owned second generation Jakafi.

 

COMPANY ADDRESS
Route 141 & Henry Clay Road
Wilmington, DE 19880
United States

COMPANY PHONE
302-498-6700

COMPANY WEBSITE



Get BioInvest's perspective on Incyte's CEO


Latest Company News

Incyte Corporation (NASDAQ:INCY): Honing in on Growth Projections Midway Monitor - 4 hours ago Incyte Corporation (NASDAQ:INCY) is anticipated to report earnings of 164.34% per share for next year, according to research brokerages covering the stock. Incyte Corporation performed Very Well with a change of 0.39% in the Last Trade - Free Observer Blue-chip stocks of the day: Incyte Corporation (NASDAQ : INCY) - The News Journal [...]
Fri, Mar 24, 2017 9:33:00 PM, Continue reading at the source
Checking Out the Technicals for Incyte Corporation (INCY) The USA Commerce - 11 hours ago We have gathered the technical data on Incyte Corporation (INCY), and see some interesting trends in the stock's behavior of late. [...]
Fri, Mar 24, 2017 2:37:00 PM, Continue reading at the source
Chart Revelations As Seen From Incyte Corporation (INCY) NY Stock News - 11 hours ago The technicals for Incyte Corporation (INCY) has spoken via its technical chart and the message is loud and clear. Based on that message, this is the relevant information necessary to make sense of that current setup. [...]
Fri, Mar 24, 2017 2:26:00 PM, Continue reading at the source
Drilling Down Into Incyte Corporation (INCY) StockNewsJournal - Mar 23, 2017 Incyte Corporation (INCY) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $141.28, up from yesterday's close by 0.39%. [...]
Thu, Mar 23, 2017 5:37:00 PM, Continue reading at the source
Lookout for Price Target? Incyte Corporation (INCY), Rockwell Collins, Inc. (COL) StockNewsJournal - Mar 21, 2017 Investors who are keeping close eye on the stock of Incyte Corporation (NASDAQ:INCY) established that the company was able to keep return on investment at 9.46 in the trailing twelve month while Reuters data showed that industry's average stands at -3 ... [...]
Tue, Mar 21, 2017 12:22:00 PM, Continue reading at the source
Incyte Corporation Stock Rises on Price Target Increase TheStreet.com - Mar 13, 2017 Incyte (INCY) shares were up 1.3% to $151.21 in premarket trading Monday after analysts at Credit Suisse raised the company's price target to $174 from $136. Gilead Looking To Buy Incyte? It Makes Sense - Benzinga Why Investors remained confident on Realty Income Corporation (O), Incyte ... - StockNewsJournal [...]
Mon, Mar 13, 2017 12:18:00 PM, Continue reading at the source
Incyte Corporation at the Cowen Healthcare Conference: 4 Things You'll Want to ... Motley Fool - Mar 9, 2017 Few biotechs have enjoyed as fun a ride as Incyte Corporation (NASDAQ:INCY) in recent years. The stock has soared more than 700% since early 2012 thanks primarily to tremendous success for cancer drug Jakafi. Earnings Clues on Incyte Corporation (INCY), Mastercard Incorporated (MA ... - StockNewsJournal [...]
Thu, Mar 09, 2017 4:41:00 PM, Continue reading at the source
Penn cancer center forms research partnership with Incyte pharmaceutical company The Daily Pennsylvanian - Mar 2, 2017 Incyte Corporation, a pharmaceutical company, is entering into a multi-year research partnership with the Abramson Cancer Center at Penn. [...]
Thu, Mar 02, 2017 10:07:00 PM, Continue reading at the source
Incyte Corporation: Incyte Announces Oncology Research Alliance with the ... The Wall Street Transcript - Feb 23, 2017 BUSINESS WIRE)--Feb. 23, 2017-- Incyte Corporation (Nasdaq:INCY) today announces a multi-year research collaboration with the Abramson Cancer Center at the University of Pennsylvania. University of Pennsylvania announces cancer research alliance with Incyte - DOTmed.com [...]
Thu, Feb 23, 2017 1:15:00 PM, Continue reading at the source
Incyte: Many Strengths, Small EPS, So What's It Worth? Seeking Alpha - Feb 17, 2017 Incyte (NASDAQ:INCY) has now reported its Q4 and full-year financial results, and provided an update on its business. Since there were not a lot of surprises therein, I'll get to them later, but as I've previously said in a Dec. 5 article titled Incyte ... Seven Eight Capital LP Invests $1170000 in Incyte Corporation (INCY) - The Cerbat Gem [...]
Fri, Feb 17, 2017 6:47:00 PM, Continue reading at the source